HC Wainwright Analysts Raise Earnings Estimates for CRVS

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – HC Wainwright lifted their Q3 2025 earnings estimates for Corvus Pharmaceuticals in a report issued on Monday, August 11th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.15). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS and FY2027 earnings at ($0.40) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03.

A number of other research firms also recently issued reports on CRVS. Oppenheimer restated an “outperform” rating and set a $17.00 price objective (up previously from $15.00) on shares of Corvus Pharmaceuticals in a report on Friday, May 9th. Wall Street Zen upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Mizuho set a $11.00 target price on shares of Corvus Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, May 20th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Corvus Pharmaceuticals Stock Performance

NASDAQ CRVS opened at $5.43 on Thursday. Corvus Pharmaceuticals has a 52-week low of $2.54 and a 52-week high of $10.00. The company has a 50-day simple moving average of $4.26 and a 200 day simple moving average of $4.05. The company has a market capitalization of $404.59 million, a PE ratio of -5.38 and a beta of 0.42.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Large investors have recently modified their holdings of the business. Sender Co & Partners Inc. bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $52,000. Perceptive Advisors LLC bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $5,754,000. Bridgeway Capital Management LLC boosted its position in shares of Corvus Pharmaceuticals by 61.5% in the second quarter. Bridgeway Capital Management LLC now owns 66,700 shares of the company’s stock valued at $267,000 after acquiring an additional 25,400 shares during the period. Bank of America Corp DE boosted its position in shares of Corvus Pharmaceuticals by 34.7% in the second quarter. Bank of America Corp DE now owns 132,729 shares of the company’s stock valued at $531,000 after acquiring an additional 34,180 shares during the period. Finally, Orbimed Advisors LLC boosted its position in shares of Corvus Pharmaceuticals by 3.2% in the second quarter. Orbimed Advisors LLC now owns 7,165,006 shares of the company’s stock valued at $28,660,000 after acquiring an additional 221,352 shares during the period. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Insider Buying and Selling at Corvus Pharmaceuticals

In other news, Director Peter A. Thompson sold 1,176,332 shares of Corvus Pharmaceuticals stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $4.16, for a total value of $4,893,541.12. Following the completion of the transaction, the director owned 7,165,006 shares in the company, valued at $29,806,424.96. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 28.50% of the stock is owned by insiders.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.